|
시장보고서
상품코드
1867555
세계의 치료용 RNAi - 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)RNAi for Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 치료용 RNAi 시장 규모는 2024년에 22억 7,800만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 27.5%로 확대되어 2031년까지 131억 2,500만 달러에 이를 것으로 예측됩니다.
RNA 간섭(RNAi) 치료제는 이중나선 RNA 분자(siRNA, shRNA 등)를 이용하여 표적 유전자 발현을 선택적으로 억제하는 첨단 분자 의료 기술입니다. 이를 통해 병원성 유전자의 전사와 번역을 억제하여 다양한 유전성 질환, 희귀질환, 암, 바이러스 감염증의 정밀 치료를 실현합니다. DNA 염기서열을 변경하지 않고 RNA 수준에서 가역적, 고특이성, 저독성 개입을 가능하게 합니다. 최초의 RNAi 치료제가 승인된 이후, 이 분야는 연구에서 상업화로 빠르게 전환되고 있으며, 간, 신경계, 종양학을 표적으로 하는 분야에서 큰 잠재력을 보여주고 있습니다. 전달 시스템의 비약적인 발전과 임상 파이프라인의 확대에 따라 RNAi 치료제는 정밀의료 및 유전자 치료 산업의 전략적 핵심으로 부상하고 있습니다.
RNAi 치료제의 세계 출시는 여러 요인에 의해 가속화되고 있습니다. 유전체학 및 RNA 생물학의 발전으로 고정밀 약물 설계가 가능해졌고, 지질나노입자(LNP), GalNAc 컨쥬게이트 등 새로운 전달 기술의 발전으로 간 및 기타 조직으로의 표적 효율이 크게 향상되었습니다. 또한, 여러 국가의 규제 당국의 신속한 심사 정책으로 연구개발에서 상용화까지의 기간이 단축되고 있습니다. 주요 제약사 및 생명공학 기업들은 인수, 합병, 제휴를 통해 임상 적응증 범위를 적극적으로 확장하고 있으며, 희귀질환, 대사성 질환, 심혈관 질환에 대한 RNAi 치료제 시장 확대를 촉진하고 있습니다. RNAi 치료제는 혁신적인 잠재력을 가지고 있지만, 기술적, 상업적, 규제적 장벽에 직면해 있습니다. 전달 효율과 조직 특이성은 여전히 주요 병목현상이며, 특히 중추신경계와 고형 종양에 대한 효과적인 전달을 달성하는 것이 과제입니다. 또한, RNAi 분자는 비특이적 면역 반응과 표적 외 효과를 유발할 수 있어 안전성과 유효성 모두에 영향을 미칠 수 있습니다. 비즈니스 측면에서는 높은 제조 비용과 엄격한 품질 관리 기준이 생산 규모 확대와 수익률을 제한하고 있습니다. 지적재산권 장벽과 핵심 특허가 소수의 주요 기업에 집중되어 있는 상황은 신규 시장 진출기업에게 기술적, 법적 장벽을 더욱 높이고 있습니다. 다운스트림 시장 수요는 점점 더 세분화되고 다양해지고 있습니다. 효과적인 치료법이 부족한 희귀질환 치료는 RNAi 솔루션에 대한 의존도가 높아 조기 상용화 돌파구가 될 수 있습니다. 반면, 환자 수가 방대한 심혈관계 및 대사성 질환은 장기적인 성장 잠재력을 가지고 있습니다. 종양학 및 면역치료 분야에서 RNAi는 체크포인트 억제제, CAR-T 치료 및 기타 치료법과 함께 새로운 병용 접근법을 형성하고 있습니다. 맞춤의료와 동반진단의 부상과 함께 RNAi 치료는 정밀한 계층화 및 표적화된 개입의 임상 경로에 더욱 깊숙이 통합되어 효율성, 안전성, 통제력 향상에 대한 수요를 견인할 것입니다.
이 보고서는 치료용 RNAi 세계 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총매출액, 주요 기업의 기업 점유율과 순위에 초점을 맞추어 지역별, 국가별, 유형별, 용도별 분석을 포함하고 있습니다.
치료용 RNAi 시장 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 치료용 RNAi 관련 사업/성장 전략 수립, 시장 경쟁 평가, 현재 시장 내 자사의 위치 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Arrowhead
- Silence Therapeutics
- Benitec Biopharma
- Phio Pharmaceuticals
- RXi Pharmaceuticals
- Arrakis Therapeutics
- Benitec Biopharma
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed
유형별 부문
- siRNA
- miRNA
- shRNA
용도별 부문
- 암
- 심혈관
- B형 간염 바이러스
- 기타
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for RNAi for Therapeutic was estimated to be worth US$ 2278 million in 2024 and is forecast to a readjusted size of US$ 13125 million by 2031 with a CAGR of 27.5% during the forecast period 2025-2031.
RNA interference (RNAi) therapeutics is an advanced molecular medicine technology that utilizes double-stranded RNA molecules (such as siRNA or shRNA) to selectively silence target gene expression, thereby blocking pathogenic gene transcription or translation to achieve precise treatment of various genetic disorders, rare diseases, cancers, and viral infections. Without altering the DNA sequence, RNAi therapy offers reversible, highly specific, and low-toxicity interventions at the RNA level. Since the approval of the first RNAi drug, the field has rapidly transitioned from research to commercialization, showing immense potential in targeting the liver, nervous system, and oncology. With breakthroughs in delivery systems and expanding clinical pipelines, RNAi therapeutics is emerging as a strategic pillar in precision medicine and gene therapy industries.
The global deployment of RNAi therapeutics is accelerating, driven by multiple dimensions: breakthroughs in genomics and RNA biology have enabled higher-precision drug design; advancements in novel delivery technologies such as lipid nanoparticles (LNP) and GalNAc conjugates have significantly improved targeting efficiency to the liver and other tissues; and fast-track review policies by regulatory agencies in multiple countries have shortened the path from R&D to commercialization. Leading pharmaceutical and biotech companies are actively expanding the range of clinical indications through mergers, acquisitions, and collaborations, facilitating the market rollout of RNAi therapies in rare diseases, metabolic disorders, and cardiovascular diseases.Despite its disruptive potential, RNAi therapeutics faces technical, commercial, and regulatory hurdles. Delivery efficiency and tissue specificity remain key bottlenecks, especially in achieving effective delivery to the central nervous system and solid tumors. Additionally, RNAi molecules may trigger non-specific immune responses or off-target effects, affecting both safety and efficacy. From a business perspective, high production costs and stringent quality control standards constrain scalability and profit margins. Intellectual property barriers and the concentration of core patents among a few leading companies further raise the technical and legal thresholds for new entrants.Demand in downstream markets is becoming increasingly segmented and diversified. Rare disease treatment, lacking effective therapies, is highly reliant on RNAi solutions, making it an early commercialization breakthrough. Cardiovascular and metabolic diseases, with their vast patient populations, offer long-term growth potential. In oncology and immunotherapy, RNAi is forming novel combination approaches with checkpoint inhibitors, CAR-T, and other treatments. With the rise of personalized medicine and companion diagnostics, RNAi therapies will become more deeply integrated into precision stratification and targeted intervention clinical pathways, driving demand toward higher efficiency, safety, and controllability.
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi for Therapeutic by region & country, by Type, and by Application.
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
Market Segmentation
By Company
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Arrowhead
- Silence Therapeutics
- Benitec Biopharma
- Phio Pharmaceuticals
- RXi Pharmaceuticals
- Arrakis Therapeutics
- Benitec Biopharma
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed
Segment by Type
- siRNA
- miRNA
- shRNA
Segment by Application
- Cancer
- Cardiovascular
- HBV
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of RNAi for Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of RNAi for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of RNAi for Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 RNAi for Therapeutic Product Introduction
- 1.2 Global RNAi for Therapeutic Market Size Forecast (2020-2031)
- 1.3 RNAi for Therapeutic Market Trends & Drivers
- 1.3.1 RNAi for Therapeutic Industry Trends
- 1.3.2 RNAi for Therapeutic Market Drivers & Opportunity
- 1.3.3 RNAi for Therapeutic Market Challenges
- 1.3.4 RNAi for Therapeutic Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global RNAi for Therapeutic Players Revenue Ranking (2024)
- 2.2 Global RNAi for Therapeutic Revenue by Company (2020-2025)
- 2.3 Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies RNAi for Therapeutic Product Offered
- 2.5 Key Companies Time to Begin Mass Production of RNAi for Therapeutic
- 2.6 RNAi for Therapeutic Market Competitive Analysis
- 2.6.1 RNAi for Therapeutic Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by RNAi for Therapeutic Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 siRNA
- 3.1.2 miRNA
- 3.1.3 shRNA
- 3.2 Global RNAi for Therapeutic Sales Value by Type
- 3.2.1 Global RNAi for Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global RNAi for Therapeutic Sales Value, by Type (2020-2031)
- 3.2.3 Global RNAi for Therapeutic Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Cancer
- 4.1.2 Cardiovascular
- 4.1.3 HBV
- 4.1.4 Others
- 4.2 Global RNAi for Therapeutic Sales Value by Application
- 4.2.1 Global RNAi for Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global RNAi for Therapeutic Sales Value, by Application (2020-2031)
- 4.2.3 Global RNAi for Therapeutic Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global RNAi for Therapeutic Sales Value by Region
- 5.1.1 Global RNAi for Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global RNAi for Therapeutic Sales Value by Region (2020-2025)
- 5.1.3 Global RNAi for Therapeutic Sales Value by Region (2026-2031)
- 5.1.4 Global RNAi for Therapeutic Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America RNAi for Therapeutic Sales Value, 2020-2031
- 5.2.2 North America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe RNAi for Therapeutic Sales Value, 2020-2031
- 5.3.2 Europe RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific RNAi for Therapeutic Sales Value, 2020-2031
- 5.4.2 Asia Pacific RNAi for Therapeutic Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America RNAi for Therapeutic Sales Value, 2020-2031
- 5.5.2 South America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa RNAi for Therapeutic Sales Value, 2020-2031
- 5.6.2 Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions RNAi for Therapeutic Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States RNAi for Therapeutic Sales Value, 2020-2031
- 6.3.2 United States RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe RNAi for Therapeutic Sales Value, 2020-2031
- 6.4.2 Europe RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China RNAi for Therapeutic Sales Value, 2020-2031
- 6.5.2 China RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan RNAi for Therapeutic Sales Value, 2020-2031
- 6.6.2 Japan RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea RNAi for Therapeutic Sales Value, 2020-2031
- 6.7.2 South Korea RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia RNAi for Therapeutic Sales Value, 2020-2031
- 6.8.2 Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India RNAi for Therapeutic Sales Value, 2020-2031
- 6.9.2 India RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Alnylam Pharmaceuticals
- 7.1.1 Alnylam Pharmaceuticals Profile
- 7.1.2 Alnylam Pharmaceuticals Main Business
- 7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
- 7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.1.5 Alnylam Pharmaceuticals Recent Developments
- 7.2 Arrowhead Pharmaceuticals
- 7.2.1 Arrowhead Pharmaceuticals Profile
- 7.2.2 Arrowhead Pharmaceuticals Main Business
- 7.2.3 Arrowhead Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
- 7.2.4 Arrowhead Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.2.5 Arrowhead Pharmaceuticals Recent Developments
- 7.3 Arrowhead
- 7.3.1 Arrowhead Profile
- 7.3.2 Arrowhead Main Business
- 7.3.3 Arrowhead RNAi for Therapeutic Products, Services and Solutions
- 7.3.4 Arrowhead RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.3.5 Arrowhead Recent Developments
- 7.4 Silence Therapeutics
- 7.4.1 Silence Therapeutics Profile
- 7.4.2 Silence Therapeutics Main Business
- 7.4.3 Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions
- 7.4.4 Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.4.5 Silence Therapeutics Recent Developments
- 7.5 Benitec Biopharma
- 7.5.1 Benitec Biopharma Profile
- 7.5.2 Benitec Biopharma Main Business
- 7.5.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
- 7.5.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.5.5 Benitec Biopharma Recent Developments
- 7.6 Phio Pharmaceuticals
- 7.6.1 Phio Pharmaceuticals Profile
- 7.6.2 Phio Pharmaceuticals Main Business
- 7.6.3 Phio Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
- 7.6.4 Phio Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.6.5 Phio Pharmaceuticals Recent Developments
- 7.7 RXi Pharmaceuticals
- 7.7.1 RXi Pharmaceuticals Profile
- 7.7.2 RXi Pharmaceuticals Main Business
- 7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
- 7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.7.5 RXi Pharmaceuticals Recent Developments
- 7.8 Arrakis Therapeutics
- 7.8.1 Arrakis Therapeutics Profile
- 7.8.2 Arrakis Therapeutics Main Business
- 7.8.3 Arrakis Therapeutics RNAi for Therapeutic Products, Services and Solutions
- 7.8.4 Arrakis Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.8.5 Arrakis Therapeutics Recent Developments
- 7.9 Benitec Biopharma
- 7.9.1 Benitec Biopharma Profile
- 7.9.2 Benitec Biopharma Main Business
- 7.9.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
- 7.9.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.9.5 Benitec Biopharma Recent Developments
- 7.10 miRagen Therapeutics
- 7.10.1 miRagen Therapeutics Profile
- 7.10.2 miRagen Therapeutics Main Business
- 7.10.3 miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions
- 7.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.10.5 miRagen Therapeutics Recent Developments
- 7.11 Sylentis
- 7.11.1 Sylentis Profile
- 7.11.2 Sylentis Main Business
- 7.11.3 Sylentis RNAi for Therapeutic Products, Services and Solutions
- 7.11.4 Sylentis RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.11.5 Sylentis Recent Developments
- 7.12 Gradalis
- 7.12.1 Gradalis Profile
- 7.12.2 Gradalis Main Business
- 7.12.3 Gradalis RNAi for Therapeutic Products, Services and Solutions
- 7.12.4 Gradalis RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.12.5 Gradalis Recent Developments
- 7.13 Sirnaomics
- 7.13.1 Sirnaomics Profile
- 7.13.2 Sirnaomics Main Business
- 7.13.3 Sirnaomics RNAi for Therapeutic Products, Services and Solutions
- 7.13.4 Sirnaomics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.13.5 Sirnaomics Recent Developments
- 7.14 Silenseed
- 7.14.1 Silenseed Profile
- 7.14.2 Silenseed Main Business
- 7.14.3 Silenseed RNAi for Therapeutic Products, Services and Solutions
- 7.14.4 Silenseed RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
- 7.14.5 Silenseed Recent Developments
8 Industry Chain Analysis
- 8.1 RNAi for Therapeutic Industrial Chain
- 8.2 RNAi for Therapeutic Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 RNAi for Therapeutic Sales Model
- 8.5.2 Sales Channel
- 8.5.3 RNAi for Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
